Benzinga - The Dow Jones traded higher by around 300 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.
Alto Ingredients
- The Trade: Alto Ingredients, Inc. (NASDAQ: ALTO) Director Gilbert E Nathan acquired a total of 25,000 shares an average price of $1.84. To acquire these shares, it cost around $46 thousand.
- What’s Happening: Alto Ingredients reported worse-than-expected Q4 EPS and sales results.
- What Alto Ingredients Does: Alto Ingredients Inc is a producer of specialty alcohols and essential ingredients. The company serves five markets: Health, Home and Beauty, Food and Beverage, Essential Ingredients, and Renewable Fuels.
- The Trade: Nogin, Inc. (NASDAQ: NOGN) 10% owner Stephen Choi acquired a total 25,000 shares at an average price of $0.77. The insider spent around $19.28 thousand to buy those shares.
- What’s Happening: Nogin and Seychelles Imports LLC announced an agreement uner which Sychelles will utilize Nogin's Customer Data Platform and Marketing Automation and Marketplace Dropship.
- What Nogin Does: Nogin Inc delivers commerce as a service to leading brands in the fashion, CPG, beauty, health, and wellness industries.
Lipocine
- The Trade: Lipocine Inc. (NASDAQ: LPCN) CEO and President Mahesh Patel acquired a total of 50,000 shares at an average price of $0.33. To acquire these shares, it cost around $16.5 thousand.
- What’s Happening: Lipocine posted in-line loss for the fourth quarter.
- What Lipocine Does: Lipocine Inc is a clinical-stage biopharmaceutical company. It is focused on oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders.
3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or
remove ads
.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.